Haemonetics (HAE) Projected to Post Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE) will likely be releasing its Q4 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $1.22 per share and revenue of $329.38 million for the quarter. Haemonetics has set its FY 2025 guidance at 4.500-4.700 EPS.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Stock Up 1.8 %

Haemonetics stock opened at $63.64 on Wednesday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company’s 50-day moving average is $62.67 and its 200-day moving average is $71.54. The firm has a market capitalization of $3.20 billion, a PE ratio of 25.06, a P/E/G ratio of 1.11 and a beta of 0.32. Haemonetics has a fifty-two week low of $55.30 and a fifty-two week high of $97.97.

Analyst Ratings Changes

A number of analysts have recently issued reports on HAE shares. Needham & Company LLC cut their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Raymond James reaffirmed a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Finally, StockNews.com upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.